摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-{[4-(3-fluoropyridin-2-yl)piperazin-1-yl]methyl}-1H-benzimidazole

中文名称
——
中文别名
——
英文名称
2-{[4-(3-fluoropyridin-2-yl)piperazin-1-yl]methyl}-1H-benzimidazole
英文别名
2-{[4-(3-fluoropyridin-2-yl)piperazin-1-yl]methyl}-H1-benzimidazole;2-[[4-(3-fluoropyridin-2-yl)piperazin-1-yl]methyl]-1H-benzimidazole
2-{[4-(3-fluoropyridin-2-yl)piperazin-1-yl]methyl}-1H-benzimidazole化学式
CAS
——
化学式
C17H18FN5
mdl
——
分子量
311.362
InChiKey
DIIMPNOBUZSQDU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    48
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Discovery of 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a Dopaminergic Agent with a Novel Mode of Action for the Potential Treatment of Erectile Dysfunction
    摘要:
    A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D-4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D-4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 mumol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure-activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D-4 selective agonism in this series of analogues.
    DOI:
    10.1021/jm030505a
点击查看最新优质反应信息

文献信息

  • Benzimidazoles that are useful in treating sexual dysfunction
    申请人:——
    公开号:US20020169166A1
    公开(公告)日:2002-11-14
    The present invention relates to the use of compounds of formula (I) 1 for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
    本发明涉及使用式(I)的化合物治疗性功能障碍,以及含有式(I)化合物的组合物用于治疗性功能障碍。
  • [EN] BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION<br/>[FR] BENZIMIDAZOLES UTILES DANS LE TRAITEMENT DE TROUBLES SEXUELS
    申请人:ABBOTT LAB
    公开号:WO2002088093A1
    公开(公告)日:2002-11-07
    The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
    本发明涉及使用式(I)化合物治疗性功能障碍,以及含有式(I)化合物的组合物治疗性功能障碍。
  • [EN] BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION<br/>[FR] DERIVES DE BENZIMIDAZOLE UTILISES POUR TRAITER UN DYSFONCTIONNEMENT SEXUEL
    申请人:ABBOTT LAB
    公开号:WO2003076431A1
    公开(公告)日:2003-09-18
    The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
    本发明涉及使用式(I)的化合物治疗性功能障碍,以及含有式(I)的化合物的组合物治疗性功能障碍。
  • Benzimidazoles that are useful in treating male sexual dysfunction
    申请人:Abbott Laboratories
    公开号:US07022728B2
    公开(公告)日:2006-04-04
    The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
    本发明涉及使用式(I)化合物治疗性功能障碍以及含有式(I)化合物的组合物治疗性功能障碍。
  • BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION
    申请人:ABBOTT LABORATORIES
    公开号:EP1373220A1
    公开(公告)日:2004-01-02
查看更多